Phase 3 Focus Target cardiopulmonary therapies in Phase 3 development for high-value partnering or licensing conversations, emphasizing TNX-103 in PH-HFpEF and potential expansion opportunities in related pulmonary hypertension markets.

Financial Scale Leverage the company’s substantial funding and mid-sized revenue to position strategic collaborations with larger biopharma, offering co-development or commercialization partnerships around late-stage assets.

Leadership Appointments Engage with newly appointed CFO and CCO to align on deal structures, milestone-based financing, and commercial strategy, presenting investor-friendly partnership opportunities and clear value propositions.

Clinical Momentum Capitalize on late-breaking trial data presentations at major conferences to create timely outreach campaigns to cardiology and pulmonology buyers, KOLs, and potential licensees seeking phase-appropriate assets.

Public Signals Prepare contingency and risk-mitigation narratives around potential securities law developments to reassure investors and counterparties, while highlighting ongoing Phase 3 progress and data depth to sustain BD discussions.